FDA OKs Sanofi's Teplizumab To Help Treat Stage 3 Diabetes In Kids

FDA OKs Sanofi's Teplizumab To Help Treat Stage 3 Diabetes In Kids The FDA expanded its approval of the drug for children 8 and older who have stage 3 diabetes. Teplizumab was created to delay the progression of Type 1 diabetes. The former acting director for the Center for Drug Evaluation and Research worried that the drug’s benefits did not outweigh its risks, Stat reports. Also in the news: drug shortages; new GLP-1 drugs; remote patient monitoring; and more. https://kffhealthnews.org/morning-breakout/pharmaceuticals-061526/